Vitamin E is one of the largest vitamin products in the global market . The global demand is about 60,000 tons, and the production capacity is about 70,000 tons. The actual output is about 60,000 tons. Supply and demand are basically balanced. It is estimated that the growth rate of China's vitamin E demand is 7% to 8%, and that of other developing countries is 5% to 7%. The growth rate of vitamin E demand in developed countries is slower.
Domestic vitamin E manufacturers mainly include Zhejiang Pharmaceutical Co. , Ltd. , Zhejiang Xinhecheng Co. , Ltd. and Southwest Synthetic Pharmaceutical Co., Ltd., with an output of about 40,000 tons, accounting for 45% of the global market; the main foreign supplier is Dies MAN (DSM) and BASF (BASF), accounting for 55% of the global market. More than 80% of vitamin E raw materials are used in feed additives , and about 20% are used in medicine and food additives and cosmetics. China's exports of vitamin E is mainly to feed additives based, and DSM (DSM) and BASF BASF mainly produces pharmaceutical grade high-end products, they manipulate the global vitamin E market right to speak.
In 2012, China’s vitamin E export volume was 42,200 tons, an increase of 0.48% year-on-year; the export value was US$723 million, a year-on-year decrease of 5.69%; the average export price was US$17.15/kg, a year-on-year decrease of 6.14%.
The main export markets of China's vitamin E are the United States , Germany , the Netherlands , Japan and Belgium . In 2012, China's vitamin E exports to major markets declined to varying degrees. The average export prices to Germany and the Netherlands fell by 13.81% and 14.04%. The main reason was that the market demand for feed vitamin E fell sharply due to weak global demand. . In particular, the United States suffered a once-in-50-year drought in one summer, and the demand for feed additives dropped rapidly. In addition, the debt crisis in the Eurozone has persisted, and the destocking cycle of merchants has been prolonged, resulting in insufficient confidence in market purchases. Although Zhejiang Pharmaceuticals and major European manufacturers took the initiative to suspend production in the second half of that year, they still could not change the downward trend of the market.
Account not verified